{"id":"W4281553364","doi":"10.1016/j.cgh.2022.04.038","title":"Superior Effectiveness of Tofacitinib Compared to Vedolizumab in Anti-TNF-experienced Ulcerative Colitis Patients: A Nationwide Dutch Registry Study","year":2022,"lang":"en","type":"article","venue":"Clinical Gastroenterology and Hepatology","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":50,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Alberta","funders":"Cilag; Pfizer; DSM Nutritional Products; Dr. Falk Pharma; Amgen; Tillotts Pharma; ZonMw; Pfizer Pharmaceuticals; Celltrion; Teva Pharmaceutical Industries; Celgene; Janssen Pharmaceuticals; Gilead Sciences","keywords":"Tofacitinib; Vedolizumab; Medicine; Ulcerative colitis; Internal medicine; Janus kinase inhibitor; Gastroenterology; Inflammatory bowel disease; Calprotectin; Odds ratio; Golimumab; Infliximab; Tumor necrosis factor alpha; Rheumatoid arthritis; Disease","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003434055,0.0002691425,0.000929199,0.0005001816,0.0003902557,0.001164506,0.0005801229,0.0005240836,0.002268439],"category_scores_gemma":[0.01099174,0.0003261717,0.001303815,0.001847885,0.0002706435,0.0006796563,0.0004423049,0.0002887374,0.0003364775],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001019186,"about_ca_system_score_gemma":0.001265057,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.008772128,"about_ca_topic_score_gemma":0.01242471,"domain_scores_codex":[0.9943081,0.002536616,0.001020496,0.001258883,0.0005479103,0.0003279306],"domain_scores_gemma":[0.9903778,0.001722776,0.006056662,0.0007280054,0.0006045614,0.0005101356],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.003553186,0.0001844819,0.9886289,0.0001624202,0.001332807,0.0002367606,0.0001317834,0.0001598376,0.0002986405,0.00006695511,0.0004812343,0.004763121],"study_design_scores_gemma":[0.001433387,0.001301428,0.9910121,0.00008830649,0.001671091,0.0009369125,0.0004369683,0.0008736742,0.0002887991,0.00007734742,0.001853057,0.00002686462],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9958617,0.001268835,0.0001972696,0.00007382689,0.00001538456,0.00003901446,0.001795947,0.000003117151,0.0007448046],"genre_scores_gemma":[0.9966621,0.0005405959,0.000200009,0.00006975015,0.00001665558,0.00005134497,0.002264646,0.000008660755,0.0001863356],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008772128,"threshold_uncertainty_score":0.01816118,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01516138617283127,"score_gpt":0.3129240671885144,"score_spread":0.2977626810156832,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}